Mode
Text Size
Log in / Sign up
N/A N=6 Randomized Single-blind Treatment

BreEStim and tDCS for Neuropathic Pain Management - Healthy Subjects

Pain Management

Enrolled (actual)
6
Serious AEs
0.0%
Results posted
Dec 2020
Primary outcome: Primary: Electrical Pain Threshold (EPT) — 23.83; 22.41; 24.08; 20.41 mA

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
BreEStim (Device); tDCS active (Device); tDCS sham (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
The University of Texas Health Science Center, Houston
Primary completion
May 2016

Outcome Measures

OutcomeResultp-value
PRIMARY
Electrical Pain Threshold (EPT)
23.83; 22.41; 24.08; 20.41; 26.70; 23.77
PRIMARY
Electrical Sensation Threshold (EST)
4.05; 3.54; 3.99; 3.39; 3.95; 3.59

Summary

This study looks at the effect of combined breathing-controlled electrical stimulation (BreEStim) and transcranial direct current stimulation (tDCS) on neuropathic pain after spinal cord injury, amputation, or brain injury. The hypothesis is that a single session of combined BreEStim and tDCS will produce an additive analgesic effect. This record covers the study in a population of healthy volunteers. Note that this study will also enroll spinal cord injury patients, brain injury patients, and amputation patients and that this study as applied to these other populations will be covered in separate ClinicalTrials.gov records.

Eligibility Criteria

Inclusion Criteria

  • between 18 and 75 years
  • male and female subjects
  • healthy subjects (i.e., no recent injuries or pain)

Exclusion Criteria

  • recent injuries or pain
  • have a pacemaker, or other metal and/or implanted devices
  • have amputation in their arm(s)
  • have spinal cord injury (SCI) involving impairment of arms
  • have cognitive impairment from brain injury or are not able to follow commands, or to give consent
  • have asthma or other pulmonary disease
  • are not medically stable
  • have preexisting psychiatric disorders
  • alcohol or drug abuse
  • have a history of seizures/Epilepsy, or taking benzodiazepines, anticonvulsants, and antidepressants.
  • Mini-mental state examination (MMSE), a brief 30-point questionnaire test that is commonly used in the literature, will be used to screen for cognitive impairment. A brain injury patient with a score of 24 or lower on MMSE will be excluded.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03302780). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search